Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
Lexicon Pharmaceuticals (LXRX) filed its Q3 2025 10‑Q, reporting total revenues of $14.2 million, driven largely by $13.2 million in licensing revenue from its Novo Nordisk agreement. Net product revenue from INPEFA® was $1.0 million. The company posted a net loss of $12.8 million, a substantial improvement from a loss of $64.8 million a year ago, as operating expenses fell sharply following late‑2024 restructuring.
Cash, cash equivalents, restricted cash and short‑term investments totaled $145.0 million as of September 30, 2025, including $29.0 million in restricted cash tied to debt covenants. Lexicon repaid $45.0 million on its Oxford term loans in April, leaving $56.5 million in long‑term debt (carrying value) and a weighted average interest rate of 11.8%. The Novo Nordisk license delivered $40.7 million in year‑to‑date licensing revenue; $4.3 million of the $45.0 million upfront remained as deferred revenue at quarter‑end. The company maintains a $75 million at‑the‑market equity program available.
Lexicon Pharmaceuticals, Inc. furnished a Form 8-K to disclose that it issued a press release reporting financial results for the quarter ended September 30, 2025.
The press release is provided as Exhibit 99.1 and the company states that the information in this report and the exhibit is being furnished under Item 2.02 for results of operations and financial condition, rather than filed for purposes of Exchange Act liability or incorporation by reference.
Lexicon Pharmaceuticals (LXRX) has resolved its Nasdaq listing deficiency. On 23 Jul 2025 the company received written notice from Nasdaq Listing Qualifications confirming that LXRX’s common stock has maintained a closing bid price at or above the $1.00 threshold long enough to regain full compliance with Rule 5550(a)(2). As a result, the prior non-compliance matter is formally closed and no further action is required by the company.
The 8-K contains no financial performance data, operational updates, or strategic announcements; its sole purpose is to inform investors that the risk of delisting has been removed. Regaining compliance preserves LXRX’s access to the Nasdaq Global Select Market, supporting share liquidity and investor confidence.
Lexicon Pharmaceuticals, Inc. (LXRX) disclosed in an 8-K filing that on July 3, 2025 it received written notice from Nasdaq Listing Qualifications granting the company an additional 180-day grace period—until December 30, 2025—to regain compliance with the $1.00 minimum bid-price requirement for continued listing. To secure the extension, Lexicon applied to transfer its shares from the Nasdaq Global Select Market to the Nasdaq Capital Market; Nasdaq has approved the transfer, which will become effective at the opening of trading on July 7, 2025.
During the second compliance period, the company must deliver a closing bid price of at least $1.00 for 10 consecutive business days. Eligibility for the extension remains contingent on meeting all initial Capital Market listing standards—except the bid price—and providing written confirmation that Lexicon intends to cure the deficiency, which may include effecting a reverse stock split if necessary.
The notice prevents an immediate delisting but underlines the ongoing risk that LXRX shares could be removed from Nasdaq if compliance is not restored by year-end. Investors should monitor management’s plans—particularly any potential reverse split—and the stock’s trading performance over the coming months.